Lyka Labs News

Lyka Labs Q3FY26 Results: Revenue Drops 6.6% YoY

Lyka Labs reported Q3FY26 revenue of ₹3,072.79 lakhs, down 6.6% YoY. Standalone net profit fell to ₹27.99 lakhs from ₹269.85 lakhs in Q3FY25. Nine-month performance shows revenue decline of 10.9% YoY.

Lyka Labs Reports Net Loss of Rs 72.68 Lakhs in Q2 FY26, Defers Registered Office Relocation Decision

Lyka Labs Limited reported a net loss of Rs 72.68 lakhs for the quarter ended September 30, 2025, compared to a profit of Rs 7.20 lakhs in the same quarter last year. The pharmaceutical company's revenue declined to Rs 2,862.64 lakhs from Rs 3,013.83 lakhs year-on-year. The Board approved the quarterly financial results and decided to defer the decision on shifting the registered office. The company recognized an Expected Credit Loss provision of Rs 484.03 lakhs for international trade receivables during the quarter. Additionally, 1,08,570 preference shares worth Rs 108.57 lakhs were redeemed. The earnings per share stood at negative Rs 2.02 compared to positive Rs 0.69 in the previous year quarter.

Lyka Labs Receives NCLT Extension for Income Tax Department Response in Amalgamation Case

The National Company Law Tribunal, Ahmedabad Bench granted a final opportunity to the Income Tax Department to file their response within one week regarding the amalgamation scheme between Lyka Exports Limited and Lyka Labs Limited. The Income Tax Department had failed to comply with the previous order dated October 9, 2025, and did not submit their required reply. The NCLT has scheduled the matter for further consideration on December 4, 2025. Lyka Labs received a copy of the tribunal order on November 7, 2025.

Kunal Gandhi Acquires Additional 13.5 Lakh Shares in Lyka Labs Through Transmission

Kunal Gandhi, a promoter of Lyka Labs Limited, acquired 13,50,000 equity shares (4.08% stake) through transmission from Narendra I. Gandhi (HUF). The transaction was completed on June 27, 2023. Following this acquisition, Gandhi's individual holding increased from 10,69,152 shares (3.23%) to 24,19,152 shares (7.31%). The total promoter group holding, including persons acting in concert such as Nehal N. Gandhi, Enai Trading and Investment Private Limited, and Lyka Generics Limited, remained unchanged at 56,97,161 shares (17.22%). The company's total equity share capital stands at 3,30,90,000 shares. Lyka Labs is listed on BSE and NSE.